Tag: osimertinib

Yale study leads to FDA approval of drug to treat non-small cell lung cancer

sarah JonasResearch Results

Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.

Study Reinforces Benefit Using Targeted Therapy for Early Stage NSCLC

sarah JonasResearch Results

According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.